Entrada Therapeutics Promotes Nathan J. Dowden to President
03 January 2024 - 11:00PM
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage
biopharmaceutical company aiming to transform the lives of patients
by establishing intracellular Endosomal Escape Vehicle
(EEV™)-therapeutics as a new class of medicines, today announced
that Nathan J. Dowden, current Chief Operating Officer of Entrada
Therapeutics, has been promoted to President and Chief Operating
Officer, effective as of January 1, 2024.
“Nate has played an important role in helping to guide Entrada’s
growth and has contributed to the building of an inspired team with
the potential to make a difference for patients,” said Dipal Doshi,
Chief Executive Officer at Entrada Therapeutics. “His strategic and
operational expertise in the life science sector has helped advance
our ENTR-601-44 program into the clinic, build our diverse pipeline
of intracellular therapeutics, and establish our new headquarters
in the Boston Seaport. I’m thrilled to promote Nate to President in
addition to his current role as Chief Operating Officer, and I look
forward to his continued impact on Entrada in this expanded new
role.”
Nate joined Entrada in 2019 and has 30 years of strategy,
investment, and operational experience in the healthcare sector. He
has played a critical role in developing Entrada’s strategic and
operational capabilities, helping to scale the Company to over 150
employees and advance its lead program, ENTR-601-44, into the
clinic. Prior to Entrada, Nate served as Senior Vice President of
Corporate Development at Rubius Therapeutics, where he supported
the organization’s evolution from an early-stage discovery company
into a clinical development organization. He also spent 16 years in
Managing Director roles at the Huron Consulting Group and The
Frankel Group LLC advising biotechnology, biopharmaceutical,
diagnostic, and medical device companies. Prior experience also
included time with EY and CIGNA Healthcare. Nate holds an MBA from
the Booth School of Business at the University of Chicago and a BS
from the University of Connecticut.
“Since joining Entrada, I’ve witnessed the tremendous growth of
our team, the expanding potential of our increasingly diverse
pipeline, and important progress on drug candidates we hope will
impact patients and their families,” said Mr. Dowden. “It has been
a pleasure contributing to Entrada’s mission to treat devastating
diseases with intracellular therapeutics and I am privileged to
help continue to support the Company in my new role as President
and Chief Operating Officer.”
About Entrada Therapeutics Entrada Therapeutics
is a clinical-stage biopharmaceutical company aiming to transform
the lives of patients by establishing a new class of medicines,
Endosomal Escape Vehicle (EEV™)-therapeutics, to engage
intracellular targets that have long been considered inaccessible
and undruggable. The Company’s EEV therapeutics are designed to
enable the efficient intracellular delivery of a wide range of
therapeutics into a variety of organs and tissues, resulting in an
improved therapeutic index. Through its proprietary, highly
versatile and modular EEV platform, Entrada is building a robust
development portfolio of RNA-, antibody- and enzyme-based programs
for the potential treatment of neuromuscular, immunological, ocular
and metabolic diseases, among others. The Company’s lead
oligonucleotide programs include ENTR-601-44, ENTR-601-45 and
ENTR-601-50 for the potential treatment of people living with
Duchenne who are exon 44, 45 and 50 skipping amenable,
respectively, as well as our partnered candidate ENTR-701 for
myotonic dystrophy type 1.
For more information about Entrada, please visit our
website, www.entradatx.com, and follow us on LinkedIn.
Investor and Media ContactKarla MacDonaldChief
Corporate Affairs Officerkmacdonald@entradatx.com
A photo accompanying this announcement is available
at: https://www.globenewswire.com/NewsRoom/AttachmentNg/d32ac3d6-a5b7-42eb-89ad-53a9b8d83345
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From Apr 2024 to May 2024
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From May 2023 to May 2024